157 related articles for article (PubMed ID: 36669327)
1. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL; Manning-Geist BL; Knezevic A; Deng L; Bromberg M; Funt SA; Meisel JL; Zivanovic O; Roche KL; Sonoda Y; Gardner GJ; Grisham RN; O'Cearbhaill RE; Tew WP; Abu-Rustum NR; Chi DS; Aghajanian C; Feldman DR
Gynecol Oncol; 2023 Mar; 170():93-101. PubMed ID: 36669327
[TBL] [Abstract][Full Text] [Related]
2. Development of a risk stratification system to guide treatment for female germ cell tumors.
Meisel JL; Woo KM; Sudarsan N; Eng J; Patil S; Jacobsen EP; Murali R; Gardner GJ; Bosl GJ; Aghajanian C; Feldman DR
Gynecol Oncol; 2015 Sep; 138(3):566-72. PubMed ID: 26115974
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
4. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
6. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
8. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
[TBL] [Abstract][Full Text] [Related]
9. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
[TBL] [Abstract][Full Text] [Related]
12. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
15. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
Hentrich M; Debole J; Jurinovic V; Gerl A
J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
[TBL] [Abstract][Full Text] [Related]
16. Improved survival of poor-risk non-seminomatous germ cell tumor patients: real-world data from a single institute in Japan.
Tanuma K; Kawai K; Nitta S; Shiga M; Kawahara T; Negoro H; Onozawa M; Inoue T; Nishiyama H; Miyazaki J
Jpn J Clin Oncol; 2023 Jan; 53(1):74-79. PubMed ID: 36151048
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
18. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
[TBL] [Abstract][Full Text] [Related]
19. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R; Xia C; Krailo M; Amatruda JF; Arul SG; Billmire DF; Brady WE; Covens A; Gershenson DM; Hale JP; Hurteau J; Murray MJ; Nicholson JC; Olson TA; Pashankar F; Rodriguez-Galindo C; Shaikh F; Stark D; Frazier AL; Stoneham S
Gynecol Oncol; 2018 Aug; 150(2):253-260. PubMed ID: 29884437
[TBL] [Abstract][Full Text] [Related]
20. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
